Eduardo Lujan1, Kathleen Winter2, Jillandra Rovaris3, Qin Liu4, Dan M Granoff1. 1. Center for Immunobiology and Vaccine Development, UCSF Benioff Children's Hospital Oakland. 2. Immunization Branch, California Department of Public Health, Richmond, and. 3. Cowell Center, Santa Clara University, California; and. 4. Wistar Institute, Philadelphia, Pennsylvania.
Abstract
Background: MenB-4C is a recently licensed meningococcal serogroup B vaccine. For vaccine licensure, short-term efficacy was inferred from serum bactericidal antibody (SBA) titers against 3 antigen-specific indicator strains, which are not necessarily representative of US disease-causing strains. Methods: A total of 4923 students were immunized with MenB-4C in response to an outbreak at a university. Serum samples were obtained at 1.5-2 months from 106 students who received the recommended 2 doses and 52 unvaccinated students. Follow-up serum samples were obtained at 7 months from 42 vaccinated and 24 unvaccinated participants. SBA was measured against strains from 4 university outbreaks. Results: At 1.5-2 months, the proportion of immunized students with protective titers ≥1:4 against an isolate from the campus outbreak was 93% (95% confidence interval [CI], 87%-97%) vs 37% (95% CI, 24%-51%) in unvaccinated students. The proportion with protective titers against strains from 3 other university outbreaks was 73% (95% CI, 62%-82%) vs 26% (95% CI, 14%-41%) in unvaccinated; 71% (95% CI, 61%-79%) vs 19% (95% CI, 10%-33%) in unvaccinated; and 53% (95% CI, 42%-64%) vs 9% (95% CI, 3%-22%) in unvaccinated (P < .0001 for each strain). At 7 months, the proportion of immunized students with titers ≥1:4 was 86% (95% CI, 71%-95%) against the isolate from the campus outbreak and 57% (95% CI, 41%-72%), 38% (95% CI, 24%-54%), and 31% (95% CI, 18%-47%), respectively, for the other 3 outbreak strains. Conclusions: MenB-4C elicited short-term protective titers against 4 strains responsible for recent university campus outbreaks. By 7 months the prevalence of protective titers was <40% for 2 of the 4 outbreak strains. A booster dose of MenB-4C may be needed to maintain protective titers.
Background: MenB-4C is a recently licensed meningococcal serogroup B vaccine. For vaccine licensure, short-term efficacy was inferred from serum bactericidal antibody (SBA) titers against 3 antigen-specific indicator strains, which are not necessarily representative of US disease-causing strains. Methods: A total of 4923 students were immunized with MenB-4C in response to an outbreak at a university. Serum samples were obtained at 1.5-2 months from 106 students who received the recommended 2 doses and 52 unvaccinated students. Follow-up serum samples were obtained at 7 months from 42 vaccinated and 24 unvaccinated participants. SBA was measured against strains from 4 university outbreaks. Results: At 1.5-2 months, the proportion of immunized students with protective titers ≥1:4 against an isolate from the campus outbreak was 93% (95% confidence interval [CI], 87%-97%) vs 37% (95% CI, 24%-51%) in unvaccinated students. The proportion with protective titers against strains from 3 other university outbreaks was 73% (95% CI, 62%-82%) vs 26% (95% CI, 14%-41%) in unvaccinated; 71% (95% CI, 61%-79%) vs 19% (95% CI, 10%-33%) in unvaccinated; and 53% (95% CI, 42%-64%) vs 9% (95% CI, 3%-22%) in unvaccinated (P < .0001 for each strain). At 7 months, the proportion of immunized students with titers ≥1:4 was 86% (95% CI, 71%-95%) against the isolate from the campus outbreak and 57% (95% CI, 41%-72%), 38% (95% CI, 24%-54%), and 31% (95% CI, 18%-47%), respectively, for the other 3 outbreak strains. Conclusions: MenB-4C elicited short-term protective titers against 4 strains responsible for recent university campus outbreaks. By 7 months the prevalence of protective titers was <40% for 2 of the 4 outbreak strains. A booster dose of MenB-4C may be needed to maintain protective titers.
Authors: Han-Qing Jiang; Susan K Hoiseth; Shannon L Harris; Lisa K McNeil; Duzhang Zhu; Cuiwen Tan; Adrienne A Scott; Kristin Alexander; Kathryn Mason; Lynn Miller; Ida DaSilva; Michelle Mack; Xiao-Juan Zhao; Michael W Pride; Lubomira Andrew; Ellen Murphy; Michael Hagen; Roger French; Ashoni Arora; Thomas R Jones; Kathrin U Jansen; Gary W Zlotnick; Annaliesa S Anderson Journal: Vaccine Date: 2010-07-07 Impact factor: 3.641
Authors: Matthew D Snape; Tom Dawson; Philipp Oster; Anita Evans; Tessa M John; Brigitte Ohene-Kena; Jamie Findlow; Ly-Mee Yu; Ray Borrow; Ellen Ypma; Daniela Toneatto; Andrew J Pollard Journal: Pediatr Infect Dis J Date: 2010-11 Impact factor: 2.129
Authors: Peter T Beernink; Jutamas Shaughnessy; Emily M Braga; Qin Liu; Peter A Rice; Sanjay Ram; Dan M Granoff Journal: J Immunol Date: 2011-02-16 Impact factor: 5.422
Authors: Sema Mandal; Henry M Wu; Jessica R MacNeil; Kimberly Machesky; Jocelyn Garcia; Brian D Plikaytis; Kim Quinn; Larry King; Susanna E Schmink; Xin Wang; Leonard W Mayer; Thomas A Clark; James R Gaskell; Nancy E Messonnier; Mary DiOrio; Amanda C Cohn Journal: Clin Infect Dis Date: 2013-04-17 Impact factor: 9.079
Authors: Hope H Biswas; George S Han; Kristen Wendorf; Kathleen Winter; Jennifer Zipprich; Tara Perti; Linda Martinez; Aileen Arellano; Jennifer L Kyle; Peng Zhang; Kathleen Harriman Journal: MMWR Morb Mortal Wkly Rep Date: 2016-05-27 Impact factor: 17.586
Authors: Jenny MacLennan; George Kafatos; Keith Neal; Nick Andrews; J Claire Cameron; Richard Roberts; Meirion R Evans; Kathy Cann; David N Baxter; Martin C J Maiden; James M Stuart Journal: Emerg Infect Dis Date: 2006-06 Impact factor: 6.883
Authors: Sarah A Mbaeyi; Catherine H Bozio; Jonathan Duffy; Lorry G Rubin; Susan Hariri; David S Stephens; Jessica R MacNeil Journal: MMWR Recomm Rep Date: 2020-09-25
Authors: Kelsey Sharkey; Peter T Beernink; Joanne M Langley; Soren Gantt; Caroline Quach; Christina Dold; Qin Liu; Manuel Galvan; Dan M Granoff Journal: mSphere Date: 2019-07-03 Impact factor: 4.389